Clover Health Investments Corp (CLOV) concluded trading on Wednesday at a closing price of $3.77, with 12.9 million shares of worth about $48.64 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -10.24% during that period and on May 07, 2025 the price saw a gain of about 12.54%. Currently the company’s common shares owned by public are about 510.91M shares, out of which, 384.06M shares are available for trading.
Stock saw a price change of 10.88% in past 5 days and over the past one month there was a price change of 17.45%. Year-to-date (YTD), CLOV shares are showing a performance of 19.68% which increased to 442.45% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.70 but also hit the highest price of $4.87 during that period. The average intraday trading volume for Clover Health Investments Corp shares is 5.57 million. The stock is currently trading 7.47% above its 20-day simple moving average (SMA20), while that difference is up 4.63% for SMA50 and it goes to 9.79% higher than SMA200.
Clover Health Investments Corp (NASDAQ: CLOV) currently have 510.91M outstanding shares and institutions hold larger chunk of about 18.28% of that.
The stock has a current market capitalization of $1.91B and its 3Y-monthly beta is at 2.00. It has posted earnings per share of -$0.05 in the same period. It has a debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLOV, volatility over the week remained 5.69% while standing at 5.13% over the month.
Stock’s fiscal year EPS is expected to drop by -49.27% while it is estimated to increase by 30.23% in next year. EPS is likely to grow at an annualized rate of 53.77% for next 5-years, compared to annual growth of -237.67% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on December 17, 2024 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by UBS stated Clover Health Investments Corp (CLOV) stock as a Neutral in their note to investors on October 07, 2024, suggesting a price target of $4 for the stock. On February 02, 2022, Cowen Upgrade their recommendations, while on February 02, 2022, Canaccord Genuity Initiated their ratings for the stock with a price target of $6. Stock get a Mkt perform rating from SVB Leerink on January 19, 2022.
